Cargando…
B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD(+) lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC and its superantigen MID/hag, associated with extra...
Autores principales: | Thurner, Lorenz, Fadle, Natalie, Regitz, Evi, Roth, Sophie, Cetin, Onur, Kos, Igor Age, Hess, Simon Mauro, Bein, Julia, Bohle, Rainer Maria, Vornanen, Martine, Sundström, Christer, de Leval, Laurence, Tiacci, Enrico, Borchmann, Peter, Engert, Andreas, Poeschel, Viola, Held, Gerhard, Schwarz, Eva C., Neumann, Frank, Preuss, Klaus-Dieter, Hoth, Markus, Küppers, Ralf, Lehmann, Karola, Hansmann, Martin-Leo, Becker, Sören L., Bewarder, Moritz, Hartmann, Sylvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690923/ https://www.ncbi.nlm.nih.gov/pubmed/37139600 http://dx.doi.org/10.3324/haematol.2023.282698 |
Ejemplares similares
-
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022) -
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022) -
Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022) -
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023) -
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)